DDInter481 DDInter782
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Eluxadoline
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Darolutamide may lead to a major life threatening interaction when taken with Berotralstat